Long-term combined α –blockers and 5- α –reductase inhibitor in bph-therapeutic effects, adherence, and predictors for withdrawal of medication

Long-term combined α –blockers and 5- α –reductase inhibitor in bph-therapeutic effects, adherence, and predictors for withdrawal of medication

Bibliographic Details
Main Authors:	Hueih Ling Ong, Chun Hou Liao, Hann-Chorng Kuo
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-06-01
Series:	Urological Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S1879522615001451

Similar Items

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
by: Hueih Ling Ong, et al.
Published: (2016-12-01)

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands
by: Marcus J. Drake, et al.
Published: (2017-05-01)

5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level
by: Victor C. Lin, et al.
Published: (2015-09-01)

DIFFERENCES IN THE EFFECTIVENESS OF SELECTIVE ALPHA BLOCKER THERAPY COMBINED WITH 5-ALPHA REDUCTASE INHIBITOR ON IPSS VALUE OF BPH LUTS PATIENTS
by: Septa Surya Wahyudi, et al.
Published: (2020-07-01)

THE EFFECT OF COMBINED α1-ADRENERGIC BLOCKERS AND PDE-5 INHIBITORS THERAPY ON IPSS, IIEF-5, QMAX AND PVR PATIENTS BPH WITH LUTS AND ERECTILE DYSFUNCTION
by: Muhammad Ridha, et al.
Published: (2017-07-01)

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
by: Xiao-Feng Xu, et al.
Published: (2020-03-01)

Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder
by: Cheng-Ling Lee, et al.
Published: (2020-01-01)

Alpha blocker prazosin for the treatment of benign prostatic hypertrophy (BPH).
by: Punekar S, et al.
Published: (1995-10-01)

Urothelial dysfunction and sensory protein expressions in patients with urological or systemic diseases and hypersensitive bladder
by: Hueih-Ling Ong, et al.
Published: (2017-09-01)

The hemodynamic interactions of the combined treatment with α-blockers and phosphodiesterase-5 inhibitors compared with α-blocker monotherapy: A systematic review and meta-analysis
by: C. Adamou, et al.
Published: (2020-07-01)

5α-reductase inhibitors impact prognosis of urothelial carcinoma
by: Chien-Sheng Wang, et al.
Published: (2020-09-01)

Predictors of anejaculation after Aquablation procedure for BPH
by: D-D. Nguyen, et al.
Published: (2020-07-01)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
by: Cheuk Fan Shum, et al.
Published: (2017-07-01)

Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH
by: Xing-Huan Wang, et al.
Published: (2015-01-01)

Behҫet’s Disease, and the Role of TNF-α and TNF-α Blockers
by: Tim van der Houwen, et al.
Published: (2020-04-01)

Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity
by: Sheng-Fu Chen, et al.
Published: (2015-07-01)

A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α-Blockers and α-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction
by: Hoon Choi, et al.
Published: (2015-12-01)

Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
by: Tina Kiguradze, et al.
Published: (2017-03-01)

Repeat suburethral sling procedure is effective for recurrent female stress urinary incontinence
by: Hueih Ling Ong, et al.
Published: (2016-06-01)

Inhibition of α-glucosidase, α-amylase, and aldose reductase by potato polyphenolic compounds.
by: Diganta Kalita, et al.
Published: (2018-01-01)

Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
by: Antonio La Torre, et al.
Published: (2021-07-01)

TNFα blockers and infectious risk in rheumatoid arthritis
by: S. Todesco, et al.
Published: (2011-06-01)

Subjective symptom improvement of silodosin treatment for BPH patients with unsatisfactory response to initial ɑ1 blocker
by: Han-Yu Weng, et al.
Published: (2016-06-01)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
by: Hamilton Robert J, et al.
Published: (2011-09-01)

Management of BPH then 2000 and now 2016 – From BPH to BPO
by: Johan Braeckman, et al.
Published: (2017-07-01)

The Role of TNF-α in Morphine Tolerance: Effect of TNF-α inhibitor Etanercept and its therapeutic implication
by: Shen, Ching-Hui, et al.
Published: (2011)

Periodontal Conditions during Arthritis Therapy with TNF-α Blockers
by: Rudolf Schiefelbein, et al.
Published: (2018-10-01)

Synthesis of Dicentrine Analogues as Potential α1-Adrenergic Blocker
by: Hsiu e Lin, et al.
Published: (1994)

Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer
by: Michael V. Fiandalo, et al.
Published: (2019-01-01)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
by: Dan-in Jang, et al.
Published: (2021-03-01)

The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates
by: Alexander B. Opoku-Acheampong, et al.
Published: (2017-07-01)

Predictors of Therapeutic Response to Beta-blockers in Patients with Heart Failure in Taiwan
by: Hsin Hu, et al.
Published: (2007-08-01)

THE EFFICACY OF DUTASTERIDE AND GREEN TEA TOWARDS BLEEDING ON BPH AFTER TURP: STUDY THEIR EFFECT ON HIF-1α EXPRESSION & HEMATOCRIT
by: Andry Irawan, et al.
Published: (2017-07-01)

Oxidative Stress in BPH
by: Murat Savas, et al.
Published: (2009-01-01)

Assessment of BPH/BOO
by: Altaf Mangera, et al.
Published: (2014-01-01)

Posters: BPH/LUTS
Published: (2008-01-01)

BPH management today
by: Altaf Mangera, et al.
Published: (2014-01-01)

Transdermal Delivery of Bioidentical Progesterone with a Steroid 5α-Reductase Inhibitor (Dutasteride): a Pilot Study
by: sara Zargar-Shoshtari, et al.
Published: (2011-01-01)

New Potent 5α- Reductase and Aromatase Inhibitors Derived from 1,2,3-Triazole Derivative
by: Mohamed El-Naggar, et al.
Published: (2020-02-01)

Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study.
by: David Robinson, et al.
Published: (2015-01-01)